Skip to main content

MoneyWorks4Me

Piramal Pharma gets nod to exercise call option to acquire balance 26% equity stake in Yapan

18 Nov 2026 Evaluate

Piramal Pharma has received approval to exercise its call option to acquire the balance 26% equity stake in Yapan Bio (Yapan), a subsidiary of the company, from its existing shareholders (the proposed transaction). The Administrative Committee of the Board of Directors of the company, acting under the authority delegated by the Board, has approved the same.

Upon completion of the proposed transaction the company’s shareholding in Yapan is expected to increase from the existing 74% to 100%, and Yapan will become a wholly owned subsidiary of the company. The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalized. Yapan is a contract development and manufacturing organization that specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Peers
Company Name CMP
Sun Pharma. Inds. 1872.30
Dr. Reddys Labs. 1396.00
Cipla 1420.00
Lupin 1968.95
Zydus Lifesciences 1195.00
View more..